TrialNature communications2023

Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4.

Yoo-Na Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.